Journal of Alzheimer's Disease Reports

An Open Access Journal

Impact Factor
2024
2.8
CiteScore
2024
2.8

Volume

8, 1 issue

Latest issue

8:1 online 09 January 2024

Next issue

9:1 scheduled for January 2025

Back volumes

From volume 1, 2017

ISSN online

2542-4823
Open Access
Online Only

Aims & Scope

The Journal of Alzheimer's Disease Reports is an open access international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, hypotheses, and case reports. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer's disease.

 

Editorial Board

Editor-in-Chief

George Perry, PhD
Department of Neuroscience,
Developmental and Regenerative Biology
University of Texas at San Antonio
One UTSA Circle
San Antonio, Texas 78249, USA
Email: george.perry@j-alz.com
ORCID: 0000-0002-6547-0172

Co-Editor-in-Chief

Paula Moreira, PhD
Faculty of Medicine, University of Coimbra
Azinhaga de Santa Comba, Celas
3000-548 Coimbra, Portugal
Email: pimoreira@fmed.uc.pt
ORCID: 0000-0001-5177-6747

Managing Editor

Beth Kumar
Email: jadreports@iospress.com 
 

Associate Editors

Tania Correa de Toledo Ferraz Alves, MD, PhD
Department of Psychiatry, Institute of Psychiatry São Paulo, Medical School, Sào Paulo, Brazil 
(late onset depression, cognition, late onset bipolar, brain imaging, AD)

J. Wesson Ashford, MD, PhD
Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Palo Alto, CA
USA
(aging, screening, dementia assessment, dementia diagnosis, apolipoprotein E)

Craig S. Atwood, PhD    
Department of Medicine, University of Wisconsin-Madison, Madison, WI
USA          
(amyloid biology, cell cycle control, endocrinology, neurodegeneration, neurodevelopment, neuroendocrinology, neuroregeneration)

Jesús Ávila, MD    
Centro de Biologia Molecular Severo Ochoa (CSIC-UAM), Madrid
Spain          
(tau protein, aging, neuron reprogramming)

María Isabel Behrens, MD, PhD
Departamento de Neurología y Neurocirugía, and Directora de Centro de Investigación Clínica Avanzada,
Hospital Clínico Universidad de Chile, Departamento de Neurociencia Facultad de Medicina, Universidad de Chile, Santiago
Chile
(Dementia, Neurodegenerative disorders, Alzheimer's Disease, Inverse Association between cancer and neurodegenerative disorders)

Rudy J. Castellani, MD    
Northwestern University, Feinberg School of Medicine, Chicago, IL
USA           
(frontotemporal lobar degeneration, traumatic brain injury, chronic traumatic encephalopathy, prion disease, neuropathology)

Sónia C. Correia, PhD
Center for Neuroscience and Cell Biology & Centre for Innovative Biomedicine and Biotechnology, University of Coimbra
Coimbra - Portugal
(Alzheimer's disease, brain metabolism, mitochondria, hypoxia)

Ding Ding, MPH, PhD
Institute of Neurology, Fudan University Huashan Hospital, Shanghai, 
China 
(Epidemiology, dementia, cohort, statistics, cognitive impairment, risk factors)

Marcia Cristina Nascimento Dourado, PhD
Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro
Brazil
(dementia, awareness, cognition, social cognition, quality of life, caregivers)

Sergio T. Ferreira, PhD    
Institute of Biophysics & Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro
Brazil            
(Aβ oligomers, neurotransmitters, mRNA translation, protein synthesis, synaptic dysfunction)

Robert Friedland, MD    
Department of Neurology, University of Louisville, Louisville, KY
USA              
(Parkinson's disease, microbiota, cognitive neurology, bacterial amyloid)

Daniela Galimberti, PhD    
Department of Biomedical, Surgical and Dental Sciences University of Milan, Milan;
Neurodegenerative Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan
Italy
(frontotemporal dementia, genetics, molecular biology, inflammation)

Saima Hilal, MD, PhD
Saw Swee Hock School of Public Health, National University of Singapore
Singapore
(dementia, cognition, cerebral small vessel disease, machine learning, MRI)

Ricardo Maccioni, PhD    
Laboratory of Neurosciences and Functional Medicine, International Center for Biomedicine, Santiago
Chile          
(neurodegeneration, tau protein, biomarkers for AD, nutraceutical compounds, multitarget therapy)

Patrizia Mecocci, MD, PhD    
Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Perugia
Italy    
(brain aging, dementia, cognitive impairment, frailty,  biomarker)

Akihiko Nunomura, MD, PhD    
Department of Psychiatry, Jikei University School of Medicine
Japan           
(brain aging, dementia, neurodegeneration, oxidative stress, RNA)

Giulio Maria Pasinetti, MD, PhD    
Department of Neurology, Mount Sinai School of Medicine, New York, NY
USA         
(Inflammasome, Microbiome, Microbiota, Mild Cognitive Impairment, Neuroinflammation)

Marwan N. Sabbagh, MD, FAAN    
Alzheimer's and Memory Disorders Division, Department of Neurology, Barrow Neurological Institute, Phoenix, AZ
USA                
(Lewy body dementia, clinical trials, drug development, therapeutics, biomarkers)

Gwenn Smith, PhD    
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD
USA
(Neuroimaging, dementia, depression, serotonin)

Xiongwei Zhu, PhD 
Department of Pathology, Case Western Reserve University, Cleveland, OH   
USA            
(mitochondrial dysfunction, oxidative stress, cell death, signal transduction)

Author Guidelines

SUBMISSION OF MANUSCRIPT

PLEASE SUBMIT YOUR MANUSCRIPT HERE

SUBMISSION POLICY

By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

Note that only papers accepted for publication are subject to payment of an article processing charge of US$1500 / €1500 to publish under the CC-BY-NC 4.0 license, or optionally US$2150 / €2150 to publish under the CC-BY 4.0 license. (There are no article submission charges for this journal.) The policy for waivers can be found below under the header "Open Access Fee Waivers". Paid fees will not be restituted if articles are withdrawn or need to be retracted after acceptance.

Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript. On submission the author(s) will be asked to provide an ORCID if available (optional) for verification purposes.

The article type (Research Report, Review, Short Communication, Hypothesis, etc.) should be clearly mentioned in the cover letter to help the editorial process.

This journal operates with single-blind peer review. If the author prefers double-blind peer review, then please submit your manuscript excluding the author listing and make sure your document is anonymized, and list your authors and affiliations only in the cover letter for the Editor. Each paper is evaluated by at least two peer reviewers and the Editor-in-Chief.

ETHICS POLICIES AND PATIENT PERMISSIONS

Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. The author must state compliance in the cover letter and in the Methods section of the article.

Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals. The author must state compliance in the cover letter and in the Methods section of the article.

Preferably patients in figures should be unrecognizable. Authors are responsible for obtaining patient permission for use of the material from all recognizable participants in photographs, videos, or other information that may be published in the Journal or on the journal’s website. A statement that permission was granted by the patient must accompany the figure legend. Do not use study participants' names, initials, or hospital numbers anywhere in the manuscript (including figures).

PREPARATION OF MANUSCRIPTS

Research Reports

Organization and style of presentation

  1. Manuscripts must be written in English. Authors whose native language is not English are advised to consult a professional English language editing service or a native English speaker prior to submission.
  2. Manuscripts should make it clear how the work is relevant to Alzheimer's disease and within the scope of JAD Reports. Be sure to include "Alzheimer's disease" in both the abstract and keywords.
  3. Nomenclature for amyloids should follow the 2018 guidelines of the International Society of Amyloidosis (ISA) nomenclature committee (Amyloid 25, 215-219, 2018), e.g., amyloid-β (Aβ) and amyloid-β protein precursor (AβPP). Also preferred is Aβ42and sAβPPα.
  4. Manuscripts should be double spaced throughout with wide margins (2.5 cm or 1 in), including the abstract and references. Every page of the manuscript, including the title page, references, tables, etc., should include a page number centered at the bottom. Do not number headings or subheadings (use all caps, italics, then underline). Footnotes should be avoided.
  5. There are no page or word limits for Research Reports but manuscripts over 10,000 words (Introduction through Discussion) should be approved by the Editor-in-Chief before submission.
  6. Manuscripts should be organized in the following order with headings and subheadings typed on a separate line, without indentation.

Title page
- Title (should be clear, descriptive and concise)
- Full name(s) of author(s)
- Full affiliation(s). Delineate affiliations with lowercase letters.
- Present address of author(s), if different from affiliation
- Running title (45 characters or less, including spaces)
- Complete correspondence address, including telephone number (optional) and e-mail address

Leave the author information blank if double-blind peer review is wished for and anonymize your document, but do include the information in the cover letter.

If any author is also a member of the Journal of Alzheimer’s Disease Reports Editorial Board, this should be declared in the Conflict of Interest Section (see instructions in the section for Conflict of Interest).

Changes in Authorship

When submitting the manuscript the author listing and order should be final. If any addition, deletion or rearrangement of author names in the authorship list does need to be made after submission, this can be done only before acceptance and with the Editor’s approval. To request such a change, the Editor must receive the following from the corresponding author: (1) the reason for the change in author list and (2) written confirmation from all authors, including the affected author, that they agree with the addition, removal or rearrangement.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an issue, any requests approved by the Editor will result in an Erratum.

Please read the IOS Press authorship policy for further information.

Abstract and Keywords

-The abstract for research papers and systematic reviews should follow the "structured abstract" format:
BACKGROUND: 
OBJECTIVE:
METHODS: 
RESULTS:
CONCLUSIONS:
The abstract should try to be no longer than 250 words.
- For other full-length papers such as Reviews and Hypotheses, the abstract should be clear, descriptive, and self-explanatory, and no longer than 250 words. Abstracts for Short Communications, Commentaries, and Editorials should be 100 words or less.

- Include a list of 4-10 keywords. These keywords should be terms from the MeSH database.

- Note that ALL articles must include an abstract.

Introduction

Provide enough information to put your work into context. Be concise. Clearly address the following points:

  • What information is already available?
  • What is the rationale or reason for your research?
  • What problem(s) does it address?

Do not include a comprehensive literature review of your research. End the Introduction by clearly stating the aims of your study.

Materials and Methods

This section should be well structured and detailed enough for others to be able to reproduce your experiments. Use clear sub-headings throughout. Start by describing the materials use, the supplier source, including any relevant catalog information, and supplier location. Use references appropriately to refer to published protocols or methodology. Do not repeat a detailed description of an already-published method or protocol.

If applicable to the study, Ethics statements and/or patient permissions must be included in the Materials and Methods section (see top of this page “ETHICS POLICIES AND PATIENT PERMISSIONS”

Results

This section should present the results and summarize the findings of your study. Do not provide any data in great detail. If you need to include additional detailed data, do so in supplementary files submitted with the paper. Consider providing a one-sentence summary at the beginning of each paragraph in the Results section, if you think that this would help the reader in understanding your findings.

Discussion

Begin this section with a brief summary of the main findings. Ensure that you answer all the questions posed in the Introduction. Mention both the strengths and the limitations for your study, as well as applications and implications of your findings. Compare these to other published findings.

Author Contributions

Please identify each author’s contribution(s) to the submission, using the guidelines of the Contributor Roles Taxonomy Project CRediT (https://credit.niso.org/). Categories include Conceptualization; Methodology; Software; Validation; Formal analysis; Investigation; Resources; Data Curation; Writing - Original Draft; Writing - Review & Editing; Visualization; Supervision; Project administration; Funding acquisition; Other. See the CRediT website for more details.

The corresponding author is responsible for ensuring that the descriptions are accurate and agreed by all authors. This information should be entered into the submission questionnaire at the time of submission. If the submission is accepted, the contributions, as entered into Editorial Manager, will be added to the manuscript file.

Example Author Contributions Statement:
Michel Jones (Conceptualization; Methodology; Formal Analysis; Investigation); 
Jennifer Smith (Data curation; Visualization; Writing - Original draft preparation); 
Jing Wang (Conceptualization; Writing - Review & Editing; Supervision; Project administration).

Acknowledgments

Include individuals or companies which have assisted with your study, including advisors, administrative support and suppliers who may have donated or given materials used in the study.

If there are no acknowledgments, then do still include this section and insert: “The authors have no acknowledgments to report.”

Funding

Include all funding sources for the study. If there is no funding involved, then do still include this section and insert: “The authors have no funding to report.”

Conflict of Interest

All affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, patents received or pending, royalties) with any organization or entity with a financial interest in, or in financial competition with, the subject matter or materials discussed in the manuscript must be completely disclosed in the submitted manuscript. See the section on "Financial Disclosure" below for more details.

If there is no conflict of interest to declare, do still include this section and insert "The authors have no conflict of interest to report". If an author is also on the Editorial Board of this journal, the following statement should be included in this section: "<AUTHOR> is an Editorial Board member of this journal, but was not involved in the peer-review process of this article nor had access to any information regarding its peer review.''

Datasets/Data Availability Statement (Required for Research Reports, Short Communications, and Systematic Reviews/Meta-Analyses). All datasets and data articles cited in your manuscript should be included in the reference list of your article (not in a separate box or in the article text). Data references should include: author name(s), dataset title, data repository, version (where available), year, and identifier (DOI/URL/etc.). Authors should include a Data Availability statement at the end of the manuscript (before the References) to describe the availability or the absence of shared data. Authors are required to deposit sequence or proteomic data into a public repository (eg. GEO, Chorus) and include a link to the repository and data, and encouraged to publicly archive their research data including, but not limited to: software, algorithms, protocols, methods, and/or materials. Exceptions are made if sharing data compromises ethical standards or legal requirements. Examples for your paper’s “Data Availability" statement:

  1. The data supporting the findings of this study are openly available in [repository name] at [DOI and/or URL]. These data were derived from the following resources available in the public domain: [list resources and URLs].
  2. The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
  3. The data supporting the findings of this study are available within the article and/or its supplementary material.
  4. Data sharing is not applicable to this article as no datasets were generated or analyzed during this study.

References
All references should be formatted in the style of Sage Vancouver. Download the EndNote style from EndNote (https://endnote.com/downloads/styles/sage-vancouver/. A .csl file is available here: https://www.zotero.org/styles/sage-vancouver)

  1. Place citations as numbers in superscript numbers in the text in order of appearance (outside punctuation; e.g., "Alzheimer's disease.1"), beginning in the text, then tables, and then figure legends. Each citation should be to one manuscript only. All publications cited in the text should be presented in a list of references following the text of the manuscript. Only articles published or accepted for publication should be listed in the reference list. Submitted articles can be listed in the text as (Author(s), unpublished data) and should NOT be numbered and included in the reference list. Personal communications should also only appear in the text (e.g., "Person name, personal communication") and not in the reference list. 2. List up to 3 authors and then use "et al."
  2. Please include doi numbers for "in press" articles if available. 4. Carefully check for and remove any duplicates (especially when using reference software). 5. References should be listed in the order of appearance in the following style:
  3. Moors TE, Milovanovic D. Defining a Lewy Body: Running Up the Hill of Shifting Definitions and Evolving Concepts? J Parkinsons Dis 2024; 14: 17-33. 2. Murphy MP and LeVine H, 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 2010; 19: 311-323. 3. Paxinos G and Watson C. The rat brain in stereotaxic coordinates. 7th ed. London: Academic Press, 2013, p. 480. 4. Langston JW, Palfreman J The Case of the Frozen Addicts. Amsterdam: IOS Press, 2014, p. 122. 5. Smith MA. Oxidative stress and iron imbalance in Alzheimer disease: how rust became the fuss! In: Perry G, Avila J, Kinoshita J, et al. (eds) Alzheimer's disease: a century of scientific and clinical research. Amsterdam: IOS Press, 2006, pp.305-308. 6. LoBue C, Munro C, Schaffert J, et al. Traumatic brain injury and risk of long-term brain changes, accumulation of pathological markers, and developing dementia: a review. In: Castellani RJ (ed) Handbook of Traumatic Brain Injury and Neurodegeneration. Amsterdam: IOS Press, 2020, pp.193-218. 7. Prince M, Comas-Herrera A, Knapp M, et al. World Alzheimer Report 2016. Improving Healthcare for People Living with Dementia: Coverage, Quality and Costs Now and in the Future. Alzheimer's Disease International, London, UK, 2016. 8. Alzheimer Research Forum. Drugs in Clinical Trials: AAB-001, http://www.alzforum.org/drg/drc/detail.asp?id=101 (2023, accessed 7 June 2024). 9. World Health Organization. Dementia, https://www.who.int/news-room/fact-sheets/detail/dementia (2023, accessed 7 June 2024). 10. Yang HS, Teng L, Kang D, et al. Cell-type-specific Alzheimer's disease polygenic risk scores are associated with distinct disease processes in Alzheimer's disease. medRxiv 2023 20230605. DOI: 10.1101/2023.06.01.23290850 [Preprint]. Posted 5 June 2023.

If you are using EndNote and the journal names are not properly abbreviating, please try updating your Journals Term List (https://support.clarivate.com/Endnote/s/article/EndNote-20-Generate-full-or-abbreviated-journal-names?language=en_US).

Datasets and Data Articles
All datasets and data articles referenced in your manuscript should be cited in the main reference list of your article (not in a separate box or in the article text).

Tables
- Number according to their sequence in the text. The text should include references to all tables.
- Provide each table on a separate page of the manuscript after the references.
- Include a brief and self-explanatory title with any explanations essential to the understanding of the table given in footnotes at the bottom of the table.
- Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.

- Citations in the tables should be numbered and included in the Reference list.

Figure Legends
The author is required to have obtained patient permission from all recognizable participants in photographs, videos, or other information that may be published in the Journal or on the journal’s website. A statement that permission was granted by the patient must accompany the figure legend. Do not use study participants' names, initials, or hospital numbers in the legend, figure, or anywhere in the manuscript.

Figures
- Number the figures according to their sequence in the text. The text should include references to all figures.
- Figures should preferably be formatted in TIF or EPS format. JPG is also acceptable.
- Figures should be designed with the format of Journal of Alzheimer’s Disease Reports in mind and preferable sized as they will appear in the PDF. A single column of the journal is 77mm and two columns are 165mm.
- Figures should be at 300 dpi or higher and be cropped to include the figure only (no blank space). CMYK is preferred for color figures.
- On figures where a scale is needed, use bar scales to avoid problems if the figure needs to be reduced.
- Each illustration should have a brief self-explanatory legend that should be typed separately from the figure in the section of the manuscript following the tables.
- Color figures are free in the electronic version of the journal (this journal is not printed).

Image Integrity
Images submitted with a manuscript for review should be minimally processed. No specific feature within an image may be enhanced, obscured, moved, removed, or introduced. The grouping or consolidation of images from multiple sources must be made explicit by the arrangement of the figure and in the figure legend. Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image and if they do not obscure, eliminate, or misrepresent any information present in the original, including backgrounds.

Unprocessed data files may be requested to help in manuscript evaluation during the peer review process or may be needed to respond to post-publication issues that may arise with published papers.

Unprocessed data and metadata files should be retained, ideally forever.

Unprocessed original images of gels and western blots must be included with submissions as Supplementary Material for reviewers to examine (not for publication). This must include the full blots, not cropped sections, with target proteins, loading controls, molecular weights, and experimental conditions clearly indicated.

Supplementary Material
Supplementary material is peer-reviewed material directly relevant to the conclusion of a paper that cannot be included in the PDF for reasons of space or medium (for example, large excel tables, movie clips or sound files). The supplement will be available for download from the publisher's content library site at the time of publication and will be made available in the format in which it was provided.

Supplementary tables and figures must have a separate numbering system from that used for tables and figures that appear in the main paper (the first figure displayed should be labeled "Supplementary Figure 1", the first table "Supplementary Table 1", and so on). References should also be cited in supplements started with [1] and listed separately.

Supplementary files are limited to 10 MB, except videos which can be up to 25 MB.

Supplementary material for Short Communications is limited to 500 words and 1 table or figure.

Review Articles
Review Articles should be authoritative and topical and provide comprehensive and balanced coverage of a timely and/or controversial issue. Review Articles should be prepared as detailed above for a Research Report, omitting Introduction through Discussion, and include a conclusion. An abstract must also be included. The length of the Review Article is at the discretion of the author but should be within reasonable limits. The Editor-in-Chief can be consulted regarding reviews of unusual length (>10,000 words).

Systematic reviews or meta-analyses that include a methods section are typically considered as a Research report and should be formatted as such.

Short Communications
A short communication is an article of original scholarship of unusual interest of less than 2000 words (Introduction through Discussion). An abstract of 100 words or less should be included with no subdivison of text into sections. References should be formatted as above. A total of three tables and/or figures are allowed.

Hypotheses
A hypothesis article should be a balanced and insightful consideration of a topic with novel hypotheses well presented and supported. The article should be prepared as a Research Report but without Methods or Results sections.

Clinical Trial Protocols
Clinical Trial Protocol articles should contain the study’s trial registration number and date of registration (mandatory), objectives, design, and methods including subject target and/or enrollment criteria. It can also include relevant scientific background and statistical information. Protocols should be submitted well before recruitment completes. Protocols for pilot or feasibility studies are not usually considered. Authors are required to include the results of the pilot as part of the protocol article. Protocols of randomized trials should follow the SPIRIT guidelines, including the SPIRIT flow diagram in the main body of the text, with the populated checklist provided as an additional file. All protocols for clinical trials must have a trial registration number and date of registration (mandatory) included as the last line of the abstract. Protocol submissions should be formatted as a Research Report omitting the “Results” section from both the abstract and the main body. Be sure to include the trial registration number and date of registration at the end of the abstract and include ethics approval and consent to participate in the methods section. All other sections and requirements/statements for a Research Report should be included.

Commentaries
Commentaries are usually commissioned and of around 1000 words with a short abstract (100 words or less) and no other subdivisions. A commentary is a short work written to discuss, prove, clarify, support, improve, or dispute a published (or soon to be published) article. A commentary typically does not include original data and discusses specific issues within a subject area rather than the whole field, explains the implications of the article, and/or puts it in context. Include an original title for your commentary (do not title it "Commentary on 'Article title'"). References should be formatted as above. If relevant, be sure to include a citation/reference to the article you are commenting on (even if "in press").

REMEMBER TO INCLUDE

In cover letter:
-
Name, postal address, phone number and e-mail address of the corresponding author.
- Name of an Associate Editor with expertise in the area of the study (if no Associate Editor is suitable, the Editorial Office will handle the submission).
- Statement that all authors have contributed to the work, agree with the presented findings, and that the work has not been published before nor is being considered for publication in another journal.
- A list of at least 6 potential reviewers knowledgeable in the area of the study and potential reviewer conflicts.
- Statement that procedures involving experimentation on animal subjects are done in accord with either the guide of the institution in which the experiments were done, or with the National Research Council's guide for the care and use of laboratory animals.

In manuscript:
-
Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be specified.
- Compliance with guidelines of animal experimentation as well as protocol approval by the Institutional Animal Care and Use Committee should be specified.
- Statement of all financial and material support for this research and any potential conflicts should also be clearly identified in the the Acknowledgments, Funding, and Conflict of Interest sections. If there are no conflict of interests then still add this statement.

Resubmissions
Resubmissions should include the manuscript number and a reference that the paper is a revision. The point-by-point response to the previous reviews should be included as a separate document. Please submit a tracked version of the paper so editors and reviewers can easily find the changes, or otherwise highlight the edited sections by color or by another detectable way.

Financial Disclosure

All affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, patents received or pending, royalties) with any organization or entity with a financial interest in, or in financial competition with, the subject matter or materials discussed in the manuscript must be completely disclosed in the submitted manuscript.

All financial and material support for the research and work must be clearly identified in the manuscript including listing of support that might constitute or give the appearance of influencing the findings. Report all support for the work reported in your manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

All authors are expected to provide disclosures to the corresponding author before submission for inclusion in the “Conflict of Interest” statement. Items included in the disclosure statement should cover: consulting fees or paid advisory boards (for the past three years or the known future), equity ownership/stock options (publicly or privately traded firms, excluding mutual funds), lecture fees when speaking at the invitation of a commercial sponsor (for the past three years or the known future), employment by the commercial entity that sponsored the study, grant support from industry, patents and/or royalties, expert witness, and other activities performed for a commercial sponsor.

PROOFS

The corresponding author of an accepted article will receive the PDF proof within 2-3 weeks' time and is asked to check this proof carefully (the publisher will execute a cursory check only). Please be sure to return your corrections as quickly as possible to ensure a timely publication date. Corrections other than typesetter's errors should be avoided, so please make sure when you submit your final revised paper to the editorial office that it is proofread and final. Costs arising from excessive corrections will be charged to the authors. Once the author’s corrections or approval to the proof are received, the article is updated and directly published in final form into the journal’s running volume. After final publication corrections will no longer be able to be made. If a significant error is discovered after publication, the only option is to publish a separate Erratum, the production of which must first be evaluated by the publisher (editorial@iospress.com).

Note: After acceptance, any additions or deletions to the list of authors MUST be approved by the Editor-in-Chief (contact jadreports@iospress.com), and all authors on the manuscript must also sign off on the changes. While the Editor considers the request, publication of the manuscript will be suspended. The author will receive a final PDF of their published article by email.

OPEN ACCESS

The Journal of Alzheimer’s Disease Reports is a fully open access journal. More information about open access publishing in IOS Press journals can be found here: IOS Press Open Library.

Policy regarding the NIH Public Access Policy mandate (PubMed Central)
All articles published in Journal of Alzheimer’s Disease Reports are automatically transferred to Pubmed Central by the publisher within 1 month from the final publication date.

Open Access Fee Waivers

A waiver request for the required publication fee should be submitted before the initial submission of a paper. Please send your title, abstract, keyword list and author listing including affiliations (and if available ORCID IDs), to the Editor-in-Chief, George Perry (george.perry@j-alz.com) with a cc to the editorial office (jadreports@iospress.com), along with your motivation for the waiver. Your request will be evaluated. Waivers are available for corresponding authors from low-income countries as identified by the Research4Life.

COPYRIGHT

Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Article sharing
Authors of journal articles are permitted to self-archive and share their work through institutional repositories, personal websites, and preprint servers. Authors have the right to use excerpts of their article in other works written by the authors themselves, provided that the original work is properly cited. The consent for sharing an article, in whole or in part, depends on the version of the article that is shared, where it is shared, and the copyright license under which the article is published. Please refer to the IOS Press Article Sharing Policy for further information.

Quoting from other publications
Authors, when quoting from someone else's work or when considering reproducing figures or tables from a book or journal article, should make sure that they are not infringing a copyright. Although in general authors may quote from other published works, permission should be obtained from the holder of the copyright if there will be substantial extracts or reproduction of tables, plates, or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.

COMPLIMENTARY COPY AND PURCHASE

Complimentary copy
The corresponding author of a contribution to this journal will receive a PDF copy of their published article on release.

An author is entitled to 25% discount on IOS Press books. See Author's Discount (25%) on all IOS Press book publications.
 

HOW TO PROMOTE YOUR WORK

Would you like some pointers on how to help your research achieve a wider reach and greater impact? Please consult our Promotional Toolkit for Authors for tips.

Please visit the IOS Press Authors page for further information.

Abstracted/Indexed in

Cabell's Guide or Directory
DOAJ: Directory of Open Access Journals
Embase
Google Scholar
Pubmed Central
Scopus
Web of Science: Emerging Sources Citation Index

Peer Review Policy

Journal of Alzheimer’s Disease Reports adheres to the Committee on Publication Ethics (COPE) code of conduct for editors and reviewers (publicationethics.org/resources/guidelines-new/cope-ethical-guidelines-peer-reviewers). Our guidelines should be read in conjunction with this broader guidance. All studies must be conducted to a high ethical standard and must adhere to local regulations and standards for gaining scrutiny and approval. Please visit our reviewer guidelines for further information about how to conduct a review.

Journal of Alzheimer’s Disease Reports operates a rigorous, timely, single-blinded peer review process (double-blind on request). After automatic plagiarism screening through iThenticate, manuscripts submitted to the journal will be assessed for suitability for publication in the journal by the Editor-in-Chief or an assigned Associate Editor. Manuscripts that are deemed unsuitable may be rejected without peer review. Manuscripts that are deemed suitable for peer review are sent to appropriate anonymous referees (a minimum of two) for confidential review. Referee reports are then assessed by the handling Editor, who will send a decision letter to the author along with the anonymized referee reports. All decision letters are approved by the Editor-in-Chief.

The initial decision will be one of the following: rejection, acceptance without revision, or potentially acceptable after minor or major revisions. Revised manuscripts will then be appraised by the Editor-in-Chief or handling Editor, who may seek the opinion of referees (prior or new) before making a final decision. Once approved this decision is then conveyed to the author along with the referee reports. Once accepted manuscripts are published online in the current Volume's run-on content.

The Editor-in-Chief has ultimate responsibility for what is published in the journal. Authors may appeal decisions by contacting the Editor-in-Chief (at jadreports@iospress.com). Authors will be informed in writing of the result of their appeal.

Impact Factor
In 2023 the Journal of Alzheimer’s Disease Reports received its first impact factor of 3.2 (Clarivate’s Journal Citation Report: Emerging Sources Citation Index). This represents an impressive first number for this quality and specialized publication. The annual JCR release enables the research and library communities to evaluate the world's high-quality academic journals using a range of journal citation indicators, descriptive data and visualizations.

Sign Up for Mailings – The open access Journal of Alzheimer's Disease Reports (JADR) publishes one volume per year. We issue quarterly mailings and you can sign up for them here.

Journal of Alzheimer’s Disease Reports has been accepted into the Directory of Open Access Journals (DOAJ) – Being included in the DOAJ is a significant milestone as it means that the journal meets the rigorous standards of the DOAJ's evaluation process, which assesses the quality, openness, and transparency of open access journals. This recognition further validates the journal's commitment to providing high-quality research to readers and ensuring that it is accessible to all. Inclusion in DOAJ is regarded as an important criterion by many funding organizations to provide their financial support to papers published in open access journals. By being part of the DOAJ, a wider audience can be reached, increasing the visibility and impact of the research achievements of the journal's community.

View News Release – To view the latest press release about a study in Volume 6 of JADR, go here. To view the open access article, go here.

JAD News – JADR's older sibling, the Journal of Alzheimer's Disease, publishes 24 volumes per year. Receive updates about new issues by signing up here. You can view JAD content here.

Latest Articles

Discover the latest articles published in the journal:

Long Objective Sleep Duration is a Marker of Cognitive Impairment in Older Adults: Findings from the Cretan Aging Cohort
Izolde Bouloukaki, Maria Basta, Eleni Skourti, Alexandros Zampetakis, Christina Alexopoulou, Andronikos Ganiaris, Marina Aligizaki, Ioannis Zaganas, ‘Panagiotis Simos, Alexandros Vgontzas

ChatGPT’s Inconsistency in the Diagnosis of Alzheimer’s Disease
Bhushan Patil, ArunSundar MohanaSundaram, Domenico Praticò

Identification of Cinnamein, a Component of Balsam of Tolu/Peru, as a New Ligand of PPARα for Plaque Reduction and Memory Protection in a Mouse Model of Alzheimer’s Disease
Sukhamoy Gorai, Mary McKay, Ramesh K. Paidi, Susanta Mondal, Kalipada Pahan

Caring for Individuals with Alzheimer’s Disease: A Spotlight on Hispanic Caregivers
Sachi Khemka, Ricardo Isaiah Garcia, Aryan Kia Roghani, Ruhananhad P. Reddy, Vasanthkumar Pattoor, Michael Jacob, Aananya Reddy, Ujala Sehar, P. Hemachandra Reddy

Automated Scoring of Alzheimer’s Disease Atrophy Scale with Subtype Classification Using Deep Learning-Based T1-Weighted Magnetic Resonance Image Segmentation
Regina E.Y. Kim, Yeong Sim Choe, Hye Weon Kim, JeeYoung Kim, Hyunji Lee, Min Kyoung Lee, Minho Lee, Keun You Kim, Se-Hong Kim, Ji-hoon Kim, Jun-Young Lee, Eosu Kim, Donghyeon Kim, Hyun Kook Lim

Supporting Diversity and Inclusion

This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.

dark blue banner for JADR author geo data for SDGs

More information will be available in due course. Check the SDGs page for updates.

JADR news signup

JADR 6:1 press release banner #1